The potential risks of expedited approval of drugs for acute bacterial infections

JAMA Internal Medicine

Volumn 174, Issue 9, 2014, Pages 1436-1437

  Floyd, James S ^a   Psaty, Bruce M ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; DALBAVANCIN; DRUG; LINEZOLID; RIFAMPICIN; SULFANILAMIDE DERIVATIVE; TEDIZOLID; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ATTRIBUTABLE RISK; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLOOD OXYGENATION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NOTE; OUTCOME ASSESSMENT; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS LOAD; ACUTE DISEASE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; METHODOLOGY; UNITED STATES;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; HUMANS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907015244     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3055     Document Type: Note

References (9)

1. US Food and Drug Administration. Guidance for industry. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/Guidances/UCM359184.pdf. Accessed May 14, 2014.
2. US Food and Drug Administration. Guidance for industry. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/Guidances/UCM358301.pdf. Accessed May 14, 2014.
3. Fleming TR, DeMets DL. Surrogate end points in clinical trials. Ann Intern Med. 1996;125(7):605-613.
4. US Food and Drug Administration. Guidance for industry. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/Guidances/UCM234907.pdf. AccessedMay 14, 2014.
5. US Food and Drug Administration. November 29, 2012 meeting of the Anti-Infective Drugs Advisory Committee. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/Drugs/Anti-infectivedrugsadvisorycommittee/ucm293600.htm. Accessed May 14, 2014.
6. US Food and Drug Administration. March 31, 2014 meeting of the Anti-Infective Drugs Advisory Committee. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/Drugs/Anti-infectivedrugsadvisorycommittee/ucm385739.htm. Accessed May 14, 2014.
7. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H. Progress on developing end points for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Clin Infect Dis. 2012;55(8):1114-1121.
8. Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010; 304(19):2172-2173.
9. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349-358.